Search

Your search keyword '"Mendes, Rodrigo E."' showing total 1,051 results
Start Over Author "Mendes, Rodrigo E."
1,051 results on '"Mendes, Rodrigo E."'

14. Activity of Aztreonam/Avibactam and Recently Approved β-Lactamase Inhibitor Combinations against Enterobacterales and Pseudomonas aeruginosa from Intensive Care Unit and Non-Intensive Care Unit Patients.

Author

Sader, Helio S., Mendes, Rodrigo E., Kimbrough, John H., Hubler, Cory M., and Castanheira, Mariana

Subjects
CEFTAZIDIME, AZTREONAM, INTENSIVE care units, PSEUDOMONAS aeruginosa, VENTILATOR-associated pneumonia, MEROPENEM
Abstract

We evaluated the activities of aztreonam/avibactam and recently approved β-lactamase inhibitor combinations (BLICs) to compare the antimicrobial susceptibility patterns of Enterobacterales and Pseudomonas aeruginosa isolated from intensive care unit (ICU) and non-ICU patients. Clinical isolates (1/patient) were consecutively collected from 72 United States medical centres in 2020–2022 and susceptibility tested by broth microdilution. The results for 5421 isolates from ICU patients were analysed and compared to those for 20,649 isolates from non-ICU patients. Isolates from ventilator-associated pneumonia patients were analysed separately. Aztreonam/avibactam inhibited 100.0%/>99.9% Enterobacterales and 100.0%/98.3% of carbapenem-resistant Enterobacterales (CRE) from ICU/non-ICU patients at ≤8 mg/L, respectively. The CRE susceptibility rates were 88.5%/82.9% for ceftazidime/avibactam, 82.1%/81.2% for meropenem/vaborbactam, and 78.2%/72.6% for imipenem/relebactam among ICU/non-ICU isolates. Among the P. aeruginosa isolates from ICU/non-ICU patients, the susceptibility rates were 96.3%/97.6% for ceftazidime/avibactam, 97.2/98.4% for ceftolozane/tazobactam, 97.1%/98.0% for imipenem/relebactam, 77.8%/84.6% for piperacillin/tazobactam, and 76.9%/85.8% for meropenem; aztreonam/avibactam inhibited 78.0%/81.9% of P. aeruginosa at ≤8 mg/L. In summary, lower susceptibility rates were observed among ICU than non-ICU isolates. Aztreonam/avibactam exhibited potent in vitro activity and broad-spectrum activity against Enterobacterales from ICU and non-ICU patients, including CRE and isolates non-susceptible to newer BLICs. Against P. aeruginosa, aztreonam/avibactam showed a spectrum of activity comparable to that of piperacillin/tazobactam, meropenem, and ceftazidime. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. 2762. Activity of Cefiderocol and Comparator Agents Against Difficult to Treat Resistance (DTR) Gram-negative Isolates, Collected During 2020-2022 as Part of SENTRY Antimicrobial Surveillance Program

Author

DeJonge, Boudewijn L, primary, Nguyen, Sean T, additional, Bryowsky, Jason J, additional, Longshaw, Christopher M, additional, Maher, Joshua, additional, Mendes, Rodrigo E, additional, Takemura, Miki, additional, and Yamano, Yoshinori, additional

Published
2023
Full Text
View/download PDF

31. 2791. Antimicrobial Activity of Cefiderocol and Comparator Agents Against Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia by Infection Type from United States Hospitals in the SENTRY Antimicrobial Surveillance Program (2020-2022)

Author

Nguyen, Sean T, primary, Valencia, Calbert, additional, Bryowsky, Jason J, additional, DeJonge, Boudewijn L, additional, Maher, Joshua, additional, Mendes, Rodrigo E, additional, Takemura, Miki, additional, and Yamano, Yoshinori, additional

Published
2023
Full Text
View/download PDF

35. 2785. Characterization of Methicillin-resistant Staphylococcus aureus Bloodstream Isolates Recovered from Patients Enrolled in a Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole for Treatment of Bacteremia, Including Infective Endocarditis

Author

Mendes, Rodrigo E, primary, Duncan, Leonard R, additional, Kimbrough, John H, additional, Holland, Thomas L, additional, Fowler, Vance G, additional, Jones, Mark E, additional, Engelhardt, Marc, additional, Smart, Jennifer, additional, and Castanheira, Mariana, additional

Published
2023
Full Text
View/download PDF

37. 2790. Activity of Cefiderocol and Comparator Agents Against Pediatric Isolates of Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia from the SENTRY Surveillance Program (2020-2022)

Author

Nguyen, Sean T, primary, DeJonge, Boudewijn L, additional, Bryowsky, Jason J, additional, Henriksen, Anne, additional, Longshaw, Christopher M, additional, Maher, Joshua, additional, Mendes, Rodrigo E, additional, Takemura, Miki, additional, and Yamano, Yoshinori, additional

Published
2023
Full Text
View/download PDF

49. 7-Year (2015–21) longitudinal surveillance of lefamulin in vitro activity against bacterial pathogens collected worldwide from patients with respiratory tract infections including pneumonia and characterization of resistance mechanisms.

Author

Paukner, Susanne, Mendes, Rodrigo E, Arends, S J Ryan, Gassner, Gisela, Gelone, Steven P, and Sader, Helio S

Subjects
*STREPTOCOCCUS pneumoniae, *RESPIRATORY infections, *PNEUMONIA, *MORAXELLA catarrhalis, *PATHOGENIC microorganisms, *HAEMOPHILUS influenzae, *SUMATRIPTAN
Abstract

Objectives Lefamulin (Xenleta™), a pleuromutilin antibiotic, was approved for the oral and IV treatment of community-acquired bacterial pneumonia (CABP) in adults in 2019/2020. This study evaluated the in vitro activity of lefamulin and comparators against 19 584 unique bacterial isolates collected from patients with community-acquired respiratory tract infections and hospitalized patients with pneumonia within the global SENTRY Antimicrobial Surveillance Program during 2015–21. Methods Isolates were susceptibility tested by the CLSI broth microdilution method, and resistance mechanisms were investigated in isolates with elevated lefamulin MICs. Results Lefamulin exhibited potent antibacterial activity against the most common and typical CABP pathogens tested, including Streptococcus pneumoniae [MIC50/90, 0.06/0.25 mg/L; 99.9% susceptible (S)], Staphylococcus aureus (MIC50/90, 0.06/0.12 mg/L; 99.6% S), Haemophilus influenzae (MIC50/90, 0.5/2 mg/L; 99.1% S) and Moraxella catarrhalis (MIC50/90, 0.06/0.12 mg/L; 100.0% S). Potent activity was also observed against the less common pneumonia pathogens: β-haemolytic (MIC50/90 of 0.03/0.06 mg/L) and viridans group Streptococcus spp. (MIC50/90 of 0.06/0.25 mg/L) and Haemophilus parainfluenzae (MIC50/90 of 1/4 mg/L). Lefamulin's activity was not adversely affected by resistance to macrolides, penicillin, tetracyclines, fluoroquinolones and other resistance phenotypes. Non-susceptibility/resistance to lefamulin was rare and primarily determined by ribosomal protection through vga (A) variants in S. aureus, overexpression of AcrAB-TolC efflux pump in H. influenzae or modifications in L3, L4 and 23SrRNA in Streptococcus spp. Conclusions Based on the coverage of the most important CABP pathogens and lacking cross-resistance, lefamulin may represent a valuable empirical treatment option for ambulatory and hospitalized patients with CABP, particularly in settings with high prevalence of resistance. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results